Senolytic and anti-aging therapeutics market to nearly double by 2030

The Business Research Company says the global market for senolytic and anti-aging therapeutics will rise from $2.18 billion in 2025 to $5.31 billion by 2030 as demand grows for treatments that target aging cells and age-related disease. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - The market is tied to a larger shift in healthcare toward extending healthy lifespans, not just treating disease after it appears. - Demand is rising as older populations grow and age-related conditions become more common. - The report points to a commercial opening for drug developers working on therapies that clear senescent cells or slow biological aging.

What happened: - The Business Research Company published a 2026 market report on senolytic and anti-aging therapeutics. - The report estimates the market will grow from $2.18 billion in 2025 to $2.6 billion in 2026. - The report projects the market will reach about $5.31 billion by 2030. - The report says the market is advancing at a 19.2% CAGR in the historical period and a 19.5% CAGR through 2030. - North America held the largest regional share in 2025. - Asia-Pacific is forecast to be the fastest-growing region during the outlook period.

The details: - Senolytic and anti-aging therapeutics are designed to selectively remove senescent cells or slow biological aging. - The goal is to improve tissue function and support a longer, healthier lifespan. - The market’s recent growth has been driven by age-related degenerative disease, weak results from traditional regenerative treatments, a larger elderly population, more funding for cellular senescence research, and early-stage longevity biotech companies. - The report says future growth will be supported by technologies that clear senescent cells, artificial intelligence in anti-aging drug discovery, personalized medicine for older patients, preventive healthcare demand, and more clinical validation of senolytic therapies. - The report highlights geroscience-driven drug development, biomarkers linked to senescence, precision longevity treatments, preventive anti-aging care, and combination therapies that blend senolytic and senomorphic approaches. - The analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The Business Research Company says it has more than 30,000 reports across 27 industries and 60+ geographies, supported by 1,500,000 datasets and the Global Market Model.

Between the lines: - The forecast suggests the sector is moving from a research-heavy niche toward a larger commercialization phase. - The strongest demand signals come from demographics and prevention, which makes the market look more durable than a trend driven only by biotech hype. - The emphasis on biomarkers, AI, and combination therapies suggests companies will need both clinical proof and better patient targeting to compete.

What's next: - The report expects the market to keep accelerating as more senolytic candidates gain clinical validation. - Growth will likely track advances in senescent-cell targeting, precision medicine, and preventive care adoption. - Download a free sample of the report - View the full market report